HRT Makes GLP-1s Work Better — The Data Most Doctors Don't Mention

Why Weight Loss Often Feels Harder During Menopause

Weight changes during menopause are common and affect a significant portion of women as they transition through midlife. Many women experience gradual increases in abdominal weight as visceral fat shifts from the hips and thighs to the midsection. Menopause is also associated with a reduction of lean muscle mass, which can lead to an overall reduction in resting metabolic rate and lead to weight gain.

Estrogen helps regulate both fat distribution and energy balance throughout the body. During perimenopause and menopause, hormonal changes may also influence insulin responses and the way energy is stored and used. However, weight changes that occur during this time are influenced by multiple factors and not estrogen alone.

Because of this, the management of weight during menopause often requires a different approach than earlier in life.

How GLP-1 Medications Help with Appetite and Metabolic Health

GLP-1 medications mimic the natural hormone glucagon-like peptide-1. These medications help regulate appetite and blood glucose responses. They also slow gastric emptying, which can help women feel full longer after eating. GLP-1 receptor agonists are among the most effective medications currently available for weight management.

The use of GLP-1s in menopause specific weight gain is still emerging, but researchers are continuing to study how hormonal changes may influence treatment responses and their use during midlife.

 “Frequently, once women have improved sleep when night sweats and hot flashes are better controlled, sometimes within a few weeks,  women note more energy and can participate in increased physical activity. The synergy of better sleep from MHT results may result in an improved experience and progress on GLP-1s .” - Dr. Stephanie Culver.

The “Hidden” Science: What Happens at the Cellular Level?

GLP-1 medications and menopausal hormone therapy work through different biologic mechanisms, but some researchers believe they may complement each other when it comes to weight loss in menopause. GLP-1 medications primarily affect appetite and blood glucose regulation, while hormone therapy may help address some of the hormonal and body composition changes associated with menopause.

Researchers are also studying how symptoms of menopause may affect long-term weight management. However, more specific research is still needed to better understand how these factors interact over time.

Can Hormone Therapy Improve GLP-1 Results?

Hormone replacement therapy during perimenopause and menopause is not considered a direct weight-loss treatment. However, improving menopause symptoms may indirectly support healthier sleep, activity, and eating patterns.

Some data suggest that women using semaglutide along with menopausal hormone therapy experienced greater weight loss than GLP-1 therapy alone. Researchers believe that several biologic pathways may contribute to these findings and current evidence remains limited with additional menopause-specific trials still needed.

NEW

Compounded Semaglutide

Starting at $70

Weekly injection. Personalized dosing for gentler starts and individual goals**

Start Now

Who Might Benefit from a Combined Approach?

Some women experience both menopause symptoms and increasing difficulty managing their weight during midlife. Clinicians often need to evaluate how symptoms of menopause affect body composition and heart disease risk.

Women earlier in menopause or within 10 years of their final menstrual period may have a favorable benefit-risk balance for hormone therapy if no contraindications exist. Treatment decisions about starting menopause hormone treatment should be individualized and adjusted based on symptoms, medical history, and long-term goals.

Is It Safe to Use GLP-1 Medications and Hormone Therapy Together?

Currently, there are no known contraindications for the use of GLP-1 medications and menopausal hormone replacement therapy together. Both therapies still require clinician evaluation for their use and ongoing monitoring. There are safety considerations and indications for their use that can depend on age, timing since menopause, and individual medical history. Women with a uterus require a progestogen along with systemic estrogen therapy to prevent the thickening of the uterine lining.

Most Popular

Estradiol Pill

Starting at $39.99

1-month supply

Best for those who want effective, multi symptom relief

Start Now

Routine screening, such as mammograms, may be recommended during ongoing hormone therapy, and follow-up with physicians/clinicians is important to determine the success of therapy and possible adjustment to dosing and route for optimization.

How to Talk with Your Clinician if Your Weight-Loss Plan Isn’t Working

Weight-management strategies during menopause sometimes need re-evaluation over time. Persistent symptoms such as poor sleep, fatigue, or hot flashes may indirectly affect treatment success.

Reviewing symptoms, medication plans, and lifestyle factors together may help identify opportunities for adjustments. The body has different needs during menopause than it did earlier in life and clinicians experienced in midlife care may consider both metabolic and hormonal contributors when building treatment plans.

Frequently Asked Questions

Why does managing weight feel more difficult during the menopause transition?

Weight changes during this time are driven by a combination of metabolic and hormonal shifts. Menopause often causes visceral fat to shift from the hips and thighs to the midsection, alongside a natural reduction in lean muscle mass. This loss of muscle lowers the body's resting metabolic rate. Additionally, fluctuating estrogen levels can alter insulin responses and change how the body stores and uses energy, meaning traditional diet and exercise strategies may no longer yield the same results.

Can menopausal hormone therapy improve the effectiveness of GLP-1 medications?

While hormone replacement therapy is not a direct treatment for weight loss, it can indirectly support weight management by alleviating disruptive symptoms like hot flashes and night sweats. Improved sleep and increased energy often make it easier to stay physically active and maintain healthy habits. Furthermore, emerging data suggest that women using semaglutide in combination with hormone therapy experienced greater weight loss than those taking a GLP-1 medication alone, though researchers note that more menopause-specific clinical trials are still needed to fully understand this relationship.

Is it safe to use GLP-1 weight loss medications and hormone replacement therapy at the same time?

There are currently no known medical contraindications that prevent someone from using GLP-1 medications and menopausal hormone therapy together. However, a combined approach requires a thorough evaluation and ongoing monitoring by a healthcare provider. Safety and dosing considerations depend on individual factors such as age, medical history, and how long it has been since the final menstrual period. Additionally, women who still have a uterus must take a progestogen alongside systemic estrogen therapy to protect the uterine lining.

References 

1. Greendale GA, Sternfeld B, Huang MH, et al. Changes in body composition and weight during the menopause transition. JCI Insight. 2019;4(5):e124865. doi:10.1172/jci.insight.124865

2. Davis SR, Castelo-Branco C, Chedraui P, et al. Understanding weight gain at menopause. Climacteric. 2012;15(5):419-429. doi:10.3109/13697137.2012.707385

3. Mahboobifard F, Pourgholami MH, Jorjani M, et al. Estrogen as a key regulator of energy homeostasis and metabolic health. Biomed Pharmacother. 2022;156:113808. doi:10.1016/j.biopha.2022.113808

4. Mikdachi H, Dunsmoor-Su R. GLP-1 receptor agonists for weight loss for perimenopausal and postmenopausal women: current evidence. Curr Opin Obstet Gynecol. 2025;37(2):97-101. doi:10.1097/GCO.0000000000000925

5. Palacios S, Chedraui P, Sanchez-Borrego R, et al. Management of obesity in menopause. Climacteric. 2024;27(4):357-363. doi:10.1080/13697137.2024.2374760 

6. Palacios S, Chedraui P, Sánchez-Borrego R, et al. Obesity and menopause. Gynecol Endocrinol. 2024;40(1):2312885. doi:10.1080/09513590.2024.2312885

7. The North American Menopause Society. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. doi:10.1097/GME.0000000000002028